We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

17 hedge funds and large institutions have $830K invested in Theriva Biologics in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0.04% → 0.04% (-0%)

1% less capital invested

Capital invested by funds: $836K → $830K (-$5.54K)

15% less funds holding

Funds holding: 20 → 17 (-3)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

75% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 4

Holders
17
Holders Change
-3
Holders Change %
-15%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
2
Reduced
4
Closed
4
Calls
$2.65M
Puts
–
Net Calls
+$2.65M
Net Calls Change
+$278K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$34.2K
2
WS
Wedbush Securities
California
+$10.6K
3
Deutsche Bank
Deutsche Bank
Germany
+$1.81K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$63.1K
2
Goldman Sachs
Goldman Sachs
New York
-$30K
3
6CM
683 Capital Management
New York
-$19K
4
UBS Group
UBS Group
Switzerland
-$11.6K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$11K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$348K -$63.1K -593 -18%
Renaissance Technologies
2
Renaissance Technologies
New York
$295K +$34.2K +321 +16%
WS
3
Wedbush Securities
California
$67K +$10.6K +100 +23%
BFM
4
Boothbay Fund Management
New York
$30K – – –
William Blair & Company
5
William Blair & Company
Illinois
$26K -$745 -7 -3%
SCA
6
Snowden Capital Advisors
New York
$23.5K – – –
BlackRock
7
BlackRock
New York
$20K – – –
Vanguard Group
8
Vanguard Group
Pennsylvania
$9K – – –
Geode Capital Management
9
Geode Capital Management
Massachusetts
$8K – – –
IA
10
IFP Advisors
Florida
$2K – – –
Deutsche Bank
11
Deutsche Bank
Germany
$2K +$1.81K +17 New
Goldman Sachs
12
Goldman Sachs
New York
– -$30K -268 Closed
6CM
13
683 Capital Management
New York
– -$19K -171 Closed
UBS Group
14
UBS Group
Switzerland
– -$11.6K -109 -99%
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
– -$11K -100 Closed
LTFS
16
Ladenburg Thalmann Financial Services
Florida
– -$1.17K -11 -92%
Victory Capital Management
17
Victory Capital Management
Texas
– -$1K -11 Closed

TOVX Hedge Fund Activity: Q4 2019 in Review

17 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q4 2019, worth a combined $830K — down 0.66% from $836K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of TOVX and 1 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 2 added.

The largest buyer was Renaissance Technologies, adding an estimated $34.2K. The largest seller was Sabby Management, cutting an estimated $63.1K.

  • 17 institutional investors held Theriva Biologics (TOVX) as of Q4 2019, down from 20 in Q3 2019.
  • Funds reported $830K of Theriva Biologics stock for Q4 2019, down 0.66% quarter-over-quarter.
  • 1 fund opened new Theriva Biologics positions in Q4 2019 and 4 closed out, a net change of -3 holders.
  • The largest Theriva Biologics buyer in Q4 2019 was Renaissance Technologies, an estimated $34.2K added.
  • The largest Theriva Biologics seller in Q4 2019 was Sabby Management, an estimated $63.1K sold.

Based on aggregated 13F filings for Q4 2019.